SCHEMBL30596392

SCHEMBL30596392

CCOC(=O)Oc1ccnc(-c2cc(OC)ccn2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.59
CCR5 P51681 1/20 0.59
CCR8 P51685 1/20 0.59
NOS3 P29474 2/20 0.47
NOS1 P29475 2/20 0.47
NOS2 P35228 2/20 0.47
JMJD6 Q6NYC1 3/20 0.42
KMT2A Q03164 2/20 0.42
GRM5 P41594 1/20 0.42
PLAU P00749 1/20 0.41
CA2 P00918 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
RIOK2 Q9BVS4 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19664384 0.80 KMT2A (0.45) NOS3NOS1NOS2JMJD6KMT2A
SCHEMBL6895062 0.80 ALDH1A1 (0.55) KMT2AL3MBTL1ALDH1A1TSHRMAPK1
SCHEMBL2549948 0.79 CCR1 (0.57) CCR1CCR5CCR8NOS3NOS1
SCHEMBL9326916 0.79 KMT2A (0.44) NOS1NOS2KMT2ACA2L3MBTL1
SCHEMBL182529 0.77 CCR1 (1.00) CCR1CCR5CCR8NOS3NOS1
SCHEMBL29395249 0.77 CCR1 (1.00) CCR1CCR5CCR8NOS3NOS1
SCHEMBL6894576 0.76 GAA (0.51) KMT2ACA2ALDH1A1TSHRKDM4E
Methane SCHEMBL21386924 0.75 CCR1 (0.95) CCR1CCR5CCR8NOS3NOS1
SCHEMBL9135460 0.75 CCR1 (0.95) CCR1CCR5CCR8NOS3NOS1
SCHEMBL8746042 0.75 CCR1 (0.95) CCR1CCR5CCR8NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195463-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) 2025-06-19 US claimed
EP-4508058-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE Faculdade de Ciencias da Universidade de Lisboa (PT) 2025-02-19 EP claimed
WO-2023199134-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) 2023-10-19 WO claimed
US-20250195463-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) 2025-06-19 US disclosed
EP-4508058-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE Faculdade de Ciencias da Universidade de Lisboa (PT) 2025-02-19 EP disclosed
WO-2023199134-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) 2023-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195463-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE SAMM50, CYP4F2, ABCB1 CCR1 2995/4885CCR5 3239/4885CCR8 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.